46 results on '"Ramael, Steven"'
Search Results
2. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)
3. Similar Pharmacokinetics of the Adalimumab (Humira®) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials
4. Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor
5. SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement
6. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial
7. The NK3 Receptor Antagonist ESN364 Suppresses Sex Hormones in Men and Women
8. Effect of Sugammadex on QT/QTc Interval Prolongation when Combined with QTc-Prolonging Sevoflurane or Propofol Anaesthesia
9. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome
10. Flucloxacillin and Diclofenac do not Cause Recurrence of Neuromuscular Blockade after Reversal with Sugammadex
11. Systemic Exposure and Implications for Lung Deposition with an Extra-Fine Hydrofluoroalkane Beclometasone Dipropionate/Formoterol Fixed Combination
12. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome
13. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects
14. Pharmacokinetic–pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects
15. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects
16. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
17. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
18. Levetiracetam Intravenous Infusion: A Randomized, Placebo-controlled Safety and Pharmacokinetic Study
19. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
20. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial
21. The neurokinin 3 receptor antagonist, fezolinetant, is effective in treatment of menopausal vasomotor symptoms: a randomized, placebo-controlled, double-blind, dose-ranging study
22. The neurokinin 3 receptor antagonist, fezolinetant, is effective in treatment of menopausal vasomotor symptoms: responder analysis results from a randomized, placebo-controlled, double-blind, dose-ranging study
23. OR33-6 The Neurokinin 3 Receptor Antagonist, Fezolinetant, Is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study
24. Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies
25. Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men
26. Additional file 2: of Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors
27. Additional file 3: of Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors
28. Additional file 1: of Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors
29. Clinical evaluation of the NK3 receptor antagonist fezolinetant (a.k.a. ESN364) for the treatment of menopausal hot flashes
30. Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers
31. First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28
32. Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors
33. EVALUATION OF THE IMMUNOGENICITY OF THE DABIGATRAN REVERSAL AGENT IDARUCIZUMAB: POOLED ANALYSIS OF PHASE I DATA
34. Investigation on the impact of continuous colonization of Bifidobacteria during early life on child’s health
35. Similar Pharmacokinetics of the Adalimumab (Humira®) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials
36. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran
37. P4‐196: The novel BACE inhibitor MK‐8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single‐ and multiple‐dose administration
38. P1-221: Safety and pharmacokinetics of the novel BACE inhibitor MK-8931 in healthy subjects following single- and Multiple-Dose administration
39. Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals
40. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
41. First Human Exposure to Org 25969
42. First Human Exposure of Org 25969, a Novel Agent to Reverse the Action of Rocuronium Bromide
43. Preliminary Assessment of Org 25969 as a Reversal Agent for Rocuronium in Healthy Male Volunteers
44. The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single- and multiple-dose administration
45. Safety and pharmacokinetics of the novel BACE inhibitor MK-8931 in healthy subjects following single- and Multiple-Dose administration
46. Flucloxacillin and diclofenac do not cause recurrence of neuromuscular blockade after reversal with sugammadex.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.